Belgium· BE-AMP-SAM533164-00

Aimovig 70 mg

A erenumab product containing erenumab, registered in Belgium by Novartis Europharm. The same ATC class is registered in 13 of our 19 countries.

ATC N02CD01

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedAimovig 70 mgATCN02CD01REGISTER NO.BE-AMP-SAM533164-00PACKS LISTED0CHECKEDSeptember 26, 2026

Where it is registered

Erenumab is registered in 13 of 19 countries.

Countries holding a registration under ATC N02CD01 (erenumab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose

Erenumab · ATC N02CD01

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Erenumab
Manufacturer
Novartis Europharm
Country
Belgium (BE)
ATC code
N02CD01
ATC class
Erenumab
Defined daily dose
2.5 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Erenumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All erenumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Aimovig
  • Liechtenstein · Aimovig
  • Norway · Aimovig

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/56528f95-e58d-443e-82c4-35ef9f2a3dac
GET /v1/drugs/56528f95-e58d-443e-82c4-35ef9f2a3dac?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled syringe",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Aimovig 70 mg",
  "name_fr": "Aimovig 70 mg",
  "name_nl": "Aimovig 70 mg",
  "amp_code": "SAM533164-00",
  "strengths": [
    "70.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Erenumab",
    "Sodium Hydroxide",
    "Sucrose",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Erenumab",
  "authorisation_numbers": [
    "EU/1/18/1293/003"
  ]
}

See everything about erenumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.